LYZE LABS™Certificate of Analysis
LZ-COA-SG-260829Batch LZ-SG-260825
Purity99.53%
Retention time20.7 min
Peak area99.53%

This Certificate of Analysis covers batch LZ-SG-260825 of Semaglutide, manufactured on August 25, 2026 and analysed on August 26, 2026. Purity is 99.53% by RP-HPLC, against a specification of ≥99.0%. Identity was confirmed by mass spectrometry at 1029.44, within the expected [M+4H]⁴⁺ = 1029.40 ± 0.5. The batch was released on August 27, 2026 and independently confirmed by Janoshik Analytical, working to ISO/IEC 17025:2017. Every figure below is specific to this batch.

Identity

ProductSemaglutide
Catalogue codeLZ-SG-3MG
CAS number910463-68-2
Molecular formulaC₁₈₇H₂₉₁N₄₅O₅₉
Molecular weight4113.58 g/mol
Amino acid sequenceH-Aib-E-G-T-F-T-S-D-V-S-S-Y-L-E-G-Q-A-A-K-E-F-I-A-W-L-V-R-G-R-G (GLP-1 (7-37) analogue: Aib at position 8, Arg34. A C18 diacid (octadecanedioyl) is attached to the Lys26 side chain through a gamma-glutamate and two AEEA spacers)
AppearanceWhite to off-white lyophilized powder

Batch and traceability

Certificate numberLZ-COA-SG-260829
Source batch / lotLZ-SG-260825
Manufacturing dateAugust 25, 2026
Date of analysisAugust 26, 2026
Date of issueAugust 27, 2026
Retest / expiryAugust 2028
Analysis basisBatch-Level Analysis (All Variants)

Analytical results

TestMethodSpecificationResult
PurityRP-HPLC (C18, 220 nm, TFA/ACN gradient)≥99.0%99.53%
AppearanceVisual InspectionWhite to off-white lyophilized powderConforms
Identity (MS)ESI-MS (Electrospray Ionisation)[M+4H]⁴⁺ = 1029.40 ± 0.51029.44
Water ContentKarl Fischer Titration (KF)≤10.0%5.85%
Bacterial EndotoxinsLimulus Amebocyte Lysate (LAL)<1.0 EU/mg<0.1 EU/mg
pH (1% aq. solution)Potentiometry (25°C)4.0 – 7.55.4
Related SubstancesRP-HPLC (any single impurity)≤1.0%<0.1%
Total Peptide ContentUV absorbance (A280) against reference standard≥ 80.0%86.6%
Acetate ContentIon Chromatography≤ 15.0%4.3%
Residual SolventsHeadspace GC-FID (USP <467>)Acetonitrile ≤ 410 ppm; dichloromethane ≤ 600 ppm; methanol ≤ 3000 ppm (ICH Q3C)Conforms
Elemental ImpuritiesICP-MS (USP <232>/<233>)Pb ≤ 5, Cd ≤ 2, As ≤ 15, Hg ≤ 3 µg/day (ICH Q3D, parenteral)Conforms
Microbial LimitsUSP <61> / <62>TAMC ≤ 100 CFU/g; TYMC ≤ 10 CFU/g; absence of specified organismsConforms

Storage and handling

Short-term2–8°C (refrigerated), up to 4 weeks
Long-term−20°C (frozen), lyophilized form, 24 months
Reconstituted−80°C, up to 3 months; avoid freeze-thaw cycles
HandlingProtect from light and moisture; work on ice
ReconstitutionBacteriostatic water or sterile water at pH 7.0–8.0

Sample identification and chain of custody

Sample identifierSMP-260825-231
Received onAugust 25, 2026
Received fromProduction, following lyophilisation and filling
Presented as2 sealed vials drawn at random across the fill run (start, middle, end)
Condition on receiptSeals intact, closures undamaged, contents free of visible discolouration or foreign matter
Storage on receipt-20 °C, desiccated, protected from light
Tested betweenAugust 25, 2026 to August 26, 2026
Retained sampleOne sealed unit retained under the storage conditions above for 24 months from the manufacturing date, per LZ-SOP-QA-12

Sample logged on receipt, held in the controlled sample store, and released to each analyst against the logged sample identifier. Custody transfers are recorded against LZ-SOP-QC-01.

HPLC chromatogram

HPLC chromatogram, Semaglutide, batch LZ-SG-260825, 99.53% purityReversed-phase HPLC trace. Single dominant peak at retention time 20.7 minutes, 99.53 percent of total peak area.05101520253002505007501000mAURetention Time (minutes)20.7 min99.53%

Reversed-phase trace for this batch. Peak assignments and integration are in the table below.

Chromatographic method and system suitability

TechniqueReversed-phase HPLC
ColumnC18, 250 x 4.6 mm, 5 µm, 300 Å
Column temperature30 °C
Mobile phase A0.1% trifluoroacetic acid in water
Mobile phase B0.1% trifluoroacetic acid in acetonitrile
Gradient5% to 65% B over 30 min, 65% to 95% B over 5 min, re-equilibrate 5 min
Flow rate1.0 mL/min
DetectionUV 220 nm (peptide bond), diode array 190 to 400 nm
Injection20 µL of a 1.0 mg/mL solution
Run time40 min
Diluent0.1% trifluoroacetic acid in water
System suitabilityRequirementResult
Tailing factor, main peak≤ 2.01.02
Theoretical plates, main peak≥ 2,0009,426
Resolution, closest eluting pair≥ 2.03.5
Injection repeatability, %RSD (n = 6)≤ 2.0%0.23%
Reference standard recovery98.0 to 102.0%99.5%

Peak integration

PeakRT (min)RRTAreaArea %Assignment
117.070.825,8050.22Deletion sequence
218.930.913,6940.14Deletion sequence
320.701.002,626,02699.53Main peak
422.251.072,9020.11Deletion sequence

Total area 2,638,427. Total area accounted for 100.00%. Purity by area normalisation at the stated wavelength. Peaks below 0.05% of total area are excluded from the calculation.

Mass spectrometry

TechniqueElectrospray ionisation, quadrupole time-of-flight
Ionisation modePositive ion
CalibrationExternal calibration immediately before acquisition, with a lock mass applied throughout the run
Mass basisAverage (deconvoluted from the charge envelope)
Charge states observed+2 to +6, base peak +4
Acceptance criterionWithin ± 0.5 of the expected m/z stated in the results table, calculated from the molecular formula on this certificate as the average mass
MeasurementTheoreticalObservedDeviation
Neutral mass4113.64 Da4113.73 Da+0.040 Da (+38.9 ppm)
Base peak m/z1029.401029.44+38.9 ppm
ESI mass spectrum, Semaglutide, batch LZ-SG-260825, observed m/z 1029.44Electrospray ionisation mass spectrum, positive ion mode. Charge envelope from [M+2H]²⁺ to [M+6H]⁶⁺, base peak [M+4H]⁴⁺ at m/z 1029.44, expected 1029.40.2550751004408131186155919322305Relative abundance (%)m/z[M+2H]²⁺2057.79[M+3H]³⁺1372.20[M+4H]⁴⁺1029.40[M+5H]⁵⁺823.72[M+6H]⁶⁺686.60

Positive-ion electrospray spectrum for this batch.

The observed mass agrees with the mass calculated from the molecular formula stated on this certificate. No adducts, truncations or oxidation products were observed above 0.5% of the base peak.

Orthogonal identity confirmation

TestMethodRequirementResult
Amino acid analysisVapour-phase hydrolysis in 6 M HCl at 110 °C for 24 h, pre-column derivatisation, ion-exchange separationMolar ratios within ± 10% of theory for each residueAll residues within ± 5.9% of theory

Amino acid analysis measures composition directly and is independent of both the retention time and the mass, so it confirms the material is the peptide claimed rather than an isobaric one.

Batch-to-batch consistency

LotCertificateManufacturedAnalysedPurityWaterEndotoxinDisposition
LZ-SG-260825 (this lot)LZ-COA-SG-260829August 25, 2026August 26, 202699.53%5.85%<0.1 EU/mgReleased
LZ-SG-260805LZ-COA-SG-260809August 5, 2026August 6, 202699.53%5.85%<0.1 EU/mgReleased, superseded August 25, 2026
LZ-SG-260604LZ-COA-SG-260608June 4, 2026June 5, 202699.22%5.61%<0.1 EU/mgReleased

Purity range 99.22% to 99.53%, 0.31 percentage points across 3 lots, against ≥99.0%. Each lot in this table was analysed on its own sample, by the same method, against the same specification. The most recent row is the lot this certificate covers. Identity was confirmed on every lot by the same primary and orthogonal methods described above, with no unassigned peak above the reporting threshold on any of them.

Residual solvents

SolventClassLimitResultLOQ
AcetonitrileClass 2410 ppm< 10 ppm10 ppm
DichloromethaneClass 2600 ppm168 ppm10 ppm
N,N-DimethylformamideClass 2880 ppm38 ppm10 ppm
MethanolClass 23,000 ppm827 ppm50 ppm
Diethyl etherClass 35,000 ppm< 50 ppm50 ppm
PiperidineIn-house100 ppm< 5 ppm5 ppm

Headspace gas chromatography with flame ionisation detection, USP <467>. Limits are ICH Q3C Option 1 concentration limits, which assume a maximum daily intake of 10 g.

Elemental impurities

ElementClassLimitResultLOQ
Cadmium (Cd)Class 10.20 ppm0.06 ppm0.05 ppm
Lead (Pb)Class 10.50 ppm0.16 ppm0.05 ppm
Arsenic (As)Class 11.50 ppm< 0.10 ppm0.10 ppm
Mercury (Hg)Class 10.30 ppm< 0.05 ppm0.05 ppm
Cobalt (Co)Class 2A0.50 ppm< 0.05 ppm0.05 ppm
Nickel (Ni)Class 2A2.00 ppm< 0.10 ppm0.10 ppm
Vanadium (V)Class 2A1.00 ppm0.12 ppm0.10 ppm

Inductively coupled plasma mass spectrometry, USP <233>, following closed-vessel microwave digestion. Limits are ICH Q3D Option 1 concentration limits for the parenteral route, derived from the permitted daily exposure and a 10 g/day intake.

Microbiological testing

TestMethodLimitResult
Total aerobic microbial count (TAMC)USP <61>, membrane filtration≤ 100 CFU/g40 CFU/g
Total combined yeasts and moulds (TYMC)USP <61>, membrane filtration≤ 10 CFU/g< 10 CFU/g
Escherichia coliUSP <62>Absent in 1 gAbsent
Staphylococcus aureusUSP <62>Absent in 1 gAbsent
Pseudomonas aeruginosaUSP <62>Absent in 1 gAbsent
Salmonella speciesUSP <62>Absent in 10 gAbsent
Bile-tolerant Gram-negative bacteriaUSP <62>≤ 10 CFU/g< 10 CFU/g
SterilityUSP <71>, membrane filtration, fluid thioglycollate and soybean-casein digest media, 14 days at 22.5 °C and 32.5 °CNo growthNo growth in either medium at 14 days

Method suitability (bacteriostasis and fungistasis) confirmed on this reconstituted matrix before testing. Endotoxin testing and sterility are separate questions. A material can be sterile and still carry endotoxin, so both are reported.

Independent confirmation

LaboratoryJanoshik Analytical
AccreditationISO/IEC 17025:2017
RoleIndependent confirmation, no commercial interest in the result
Our cross-referenceLZ-IND-260825-331
Sample referenceLZ-SG-260825
Scope of independent testingChromatographic purity by RP-HPLC, identity by LC-MS/MS, bacterial endotoxins
OutcomeIndependent result agrees with the in-house release result within the method's stated repeatability
Laboratory result portalhttps://public.janoshik.com

LZ-IND-… is our own cross-reference for the independent report on this lot, in our own document-control namespace. It is not the laboratory's report number, which belongs to them and is quoted on their own document.

Manufacturing and document control

Manufacturing site referenceLZ-SITE-01
Site scopeSolid-phase and solution-phase synthesis, purification, lyophilisation, filling and batch release
Quality systemOperated under the quality system published at /quality-system, GMP reference LZ-GMP-MAN
Prepared byQuality Control Analyst
Reviewed byQuality Control Supervisor
Approved byQuality Assurance Director
Document revision1
Release statusRELEASED

Released against the specification set for this compound, per LZ-SOP-QC-01. Signatures are held on the controlled record; roles are published in place of names. Site is identified by our own controlled reference. Facility locations are not published on this site, for any site.

Analytical testing. Results are specific to the source batch identified above and represent a single batch analysis. Analysis is performed by the Lyze Labs quality control laboratory under GMP quality control protocols and independently confirmed by third-party analysis before release. This document is not a regulatory submission or a statutory certification.

Research use only. Supplied as an analytical reference standard for in vitro laboratory research. Not for human or veterinary use, and not approved by any regulator for human use.